Cart
sales@molnova.com
FT113
CAS No. 1630808-89-7
FT113( —— )
Catalog No. M21632 CAS No. 1630808-89-7
FT113 is a novel potent inhibitor of fatty acid synthase (fasn IC50 : 213 nM)and exhibits anti-cancer activity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 140 | Get Quote |
|
| 10MG | 244 | Get Quote |
|
| 25MG | 412 | Get Quote |
|
| 50MG | 606 | Get Quote |
|
| 100MG | 862 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameFT113
-
NoteResearch use only, not for human use.
-
Brief DescriptionFT113 is a novel potent inhibitor of fatty acid synthase (fasn IC50 : 213 nM)and exhibits anti-cancer activity.
-
DescriptionFT113 is a novel potent inhibitor of fatty acid synthase (fasn IC50 : 213 nM)and exhibits anti-cancer activity.
-
In Vitro——
-
In VivoAnimal Model:Athymic nude mice bearing MV-411 cellsDosage:5, 25, or 50 mg/kg Administration:P.O., twice daily for 16 daysResult:Caused 32 % and 50% tumor growth inhibition at 25 and 50 mg/kg, respectively in mice.
-
Synonyms——
-
PathwayMetabolic Enzyme/Protease
-
TargetFatty Acid Synthase
-
RecptorFAS
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1630808-89-7
-
Formula Weight409.41
-
Molecular FormulaC22H20FN3O4
-
Purity>98% (HPLC)
-
SolubilityDMSO:62.5 mg/mL (152.66 mM; Need ultrasonic)
-
SMILESOC1(CC1)C(=O)N1CCN(CC1)C(=O)c1ccc(cc1)-c1nc2ccc(F)cc2o1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Martin MW et al. Discovery and optimization of novel piperazines as potent inhibitors of fatty acid synthase (FASN). Bioorg Med Chem Lett. 2019 Apr 15;29(8):1001-1006.
molnova catalog
related products
-
Fasnall
Fasnall is a selective FASN inhibitor that acts through its co-factor binding sites. Fasnall shows potent anti-tumor activity in the MMTV-Neu model of HER2(+) breast cancer, particularly in combination with carboplatin.
-
ELN484228
ELN484228 is a blocker of α-synuclein which is a key protein in Parkinson’s disease.
-
Orlistat
Orlistat is a drug designed to treat obesity. Its primary function is preventing the absorption of fats from the human diet, thereby reducing caloric intake.
